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Background: Leiomyosarcoma (LMS) of the gastrointestinal tract is an extremely rare high-grade neoplasm with
poor prognosis. For advanced LMS with distant metastasis, the decision as to the choice of the most appropriate
therapeutic strategy, including chemotherapy and surgery, is difficult. Here, we present an unusual case of LMS of
the sigmoid colon with liver metastases and gastric cancer. The survival of this patient was prolonged by a
combined modality therapy involving chemotherapy and surgery.
Case presentation: A 66-year-old woman who had been diagnosed with advanced gastric cancer and multiple
liver metastases was referred to our hospital. The initial treatment with docetaxel and S-1 considerably reduced
both the gastric cancer and liver tumors; consequently we performed surgical resection. Pathological examination
revealed that no viable tumor cells remained in the stomach and chemotherapy resulted in complete remission of
the gastric cancer. The liver tumors were immunohistochemically diagnosed as LMS. A tumor of the sigmoid colon
was subsequently discovered and the liver tumors were found to have recurred. The surgically resected sigmoid
colon and liver tumors were all immunohistochemically diagnosed as LMS. These findings indicated that the
multiple liver metastases arose from the LMS in the sigmoid colon, and that they were accompanied by advanced
gastric cancer. We performed another surgical resection and administered chemotherapy to treat the recurring liver
metastases. The patient survived for 4 years and 10 months after initial presentation at our hospital.
Conclusion: Colonic LMS is rare and its joint occurrence with gastric cancer is extremely unusual. Although LMS is
a high-grade neoplasm, a multimodal therapeutic approach can increase patient survival time even when multiple
liver metastases are present.
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Leiomyosarcoma (LMS) of the gastrointestinal (GI) tract
is extremely rare, and only a few reports have been pub-
lished in reviews of GI mesenchymal tumors [1,2]. LMS
frequently metastasizes to the liver and has a poor progno-
sis. Unlike gastrointestinal stromal tumors (GIST) effective
molecular therapy is not available for LMS. Thus, the de-
cision regarding the selection of an optimal therapeutic
strategy for advanced LMS with metastasis is difficult
[1,3]. In the present case report, we describe a 66-year-old* Correspondence: yyhamai@hotmail.com
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reproduction in any medium, provided the orwoman with LMS of the sigmoid colon accompanied by
multiple liver metastases and advanced gastric cancer. The
survival of this patient was prolonged by a combination of
three surgical resections and chemotherapy.
Case presentation
A 66-year-old woman diagnosed with advanced gastric
cancer and multiple liver metastases was referred to our
hospital in March 2003. She was not a carrier of the
hepatitis virus, or an alcoholic with previous hepatic dis-
ease. Furthermore, she did not have a family history of
malignant neoplasia. Gastrointestinal fiberscopy upon
admission showed an irregular ulcerative lesion on the
anterior wall of the gastric corpus (Figure 1), and the
pathological diagnosis from the biopsy specimens wasLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Gastrointestinal fiberscope findings upon admission
of the patient. The arrows indicate the position of ulcerative lesions
on the anterior wall of the gastric corpus.
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Abdominal computed tomography (CT) images revealed
four space-occupying lesions with diameters of 2–3 cm
with internal heterogeneity due to a relative lack of ef-
fect of the contrast medium in the liver (Figure 3). This
suggested the presence of metastasis from the gastric
cancer and no enlarged lymph nodes around the
stomach. A barium enema revealed no evidence of dis-
semination or colon tumors. Based on these findings,
the patient was diagnosed with Stage IV gastric cancer
with hematogenous metastases according to the Japa-
nese Classification of Gastric Carcinoma [4].
We administered chemotherapy with docetaxel and oral
S-1 to treat the gastric cancer and liver metastases [5].
Seventeen cycles of this regimen over a period of one year
considerably reduced the gastric cancer and liver tumors,
and new cancerous lesions did not appear. However, ad-
verse effects prevented the patient from continuing withFigure 2 Microscopic findings from a biopsy specimen resected from
H&E stain × 100 (A) and× 200 (B).this regimen. We considered that all of the lesions were
completely resectable at this point, and the patient pro-
vided written informed consent to proceed with surgery at
14 months after starting chemotherapy.
Ascites and peritoneal disseminated lesions were
not evident during the procedure, which included
total gastrectomy and partial liver resections for all
liver tumors. Pathological examination revealed that
no viable tumor cells remained in the stomach and
chemotherapy resulted in complete remission of the
gastric cancer. The liver tumors were immunohisto-
chemically positive for smooth muscle actin (SMA),
desmin and h-caldesmon, and negative for c-KIT,
CD34 and S-100 (Figure 4). Furthermore, an average
of 20 mitoses per 10 high power fields was observed
in the liver tumors, which were diagnosed as being
LMS with high mitotic activity. Until that point, we
considered that the liver tumors were metastases that
had developed from the gastric cancer. However, the
histological type of the liver tumors was LMS and
not adenocarcinoma. Thus, we had to assume that
the liver LMSs were primary tumors that developed
from liver or metastatic tumors from an unknown
primary LMS.
We administered only oral S-1 as adjuvant chemother-
apy after the surgery. However, 11 months after this treat-
ment, four liver tumors developed and we changed the
chemotherapy to irinotecan and cisplatin. This regimen
was ineffective and the liver tumors gradually enlarged.
Furthermore, a tumor-like mass in the sigmoid colon was
incidentally discovered on CT scan and positron emission
tomography/computed tomography (PET-CT) during this
therapeutic process; this gradually increased in size to
3 cm in diameter. Colonoscopy revealed a lesion protrud-
ing from the submucosa with a normal mucosal surface
(Figure 5). Although we suspected that this tumor might
be a solitary peritoneal metastasis from gastric cancer, our
assessment was that complete resection of the colon
tumor and all of the liver tumors would be feasible.an ulcerative lesion. Poorly differentiated adenocarcinoma is evident.
Figure 3 Abdominal contrast-enhanced CT findings upon admission. Arrows indicate the positions of four heterogeneous liver tumors.
Hamai et al. BMC Gastroenterology 2012, 12:98 Page 3 of 7
http://www.biomedcentral.com/1471-230X/12/98A second surgical resection of the four liver tumors
and a partial colon resection proceeded at 2 years and
5 months after the commencement of first-line chemo-
therapy. The sigmoid colon and liver tumors were all
immunohistochemically diagnosed as LMS (Figure 6).
This finding indicated that the LMS had originated in
the sigmoid colon, and that the multiple liver metastases
had arisen from a colonic LMS that was accompanied by
advanced gastric cancer at the time of the first
admission.
The patient underwent a third liver resection to treat two
new liver metastases that developed at 7 months after the
second procedure. This was because we considered that
there might be only a limited chance of a good response to
chemotherapy in the case of the LMS, and all of the liver
metastases were also completely resectable. Thereafter, des-
pite ifosfamide and epirubicin chemotherapy followed by
dacarbazine, multiple liver and lung metastases eventually
developed and the patient died at 4 years and 10 months
after the first presentation at our hospital.
Conclusions
The incidence of LMS in the GI tract is extremely rare
and GIST account for most GI mesenchymal tumors.
Recent reports describe the classification of only three
among 262 GI mesenchymal tumors as being LMS [1],
and only seven out of 253 mesenchymal tumors as being
involved with the colon [2]. Furthermore, the reported
incidence of LMS is 3–6% among GI mesenchymal
tumors in other regions of the GI tract such as the
esophagus, duodenum and anorectum [6-8].The reported clinical features of LMS of the GI tract
are gross polypoid and intramural types that can arise
from either the muscularis mucosae or the propria
[1,2,9]. Neighboring tissue infiltration and liver metasta-
ses are common, but lymphogenic spread is rare [1,9].
LMSs are extremely high-grade neoplasms with high mi-
totic activity, and patient survival time is usually short
[2,6-8]. The barium enema and CT scan did not detect
LMS of the sigmoid colon in our patient at the first ad-
mission. This was because the intramural tumor was
probably very small and hidden in the colonic wall.
However, the LMS had high mitotic activity and had
already caused multiple liver metastases by that time. In
addition, the liver metastasis had subsequently recurred
despite complete resection of the primary site and the
initial liver metastases. LMS seems to have a very high
hematogenous metastatic potential.
The histogenetic, clinicopathological and immuno-
histochemical profiles of LMS and GIST differ [1].
Whereas GIST arises from the interstitial cell of
Cajal, LMS originates from smooth muscle cells
within the muscularis mucosa or muscularis propria
[1,9], and it lacks KIT mutations [2,6,7]. An immu-
nohistochemical analysis is essential for a definitive
diagnosis of LMS, which is regularly negative for c-
kit and CD34 and positive for smooth muscle mar-
kers such as actin, desmin and h-caldesmon [10,11].
The immunohistochemical findings of specimens
obtained from our patient after resection of the
colon and liver tumors were similar. Furthermore,
the specimens were also positive for vimentin in
Figure 5 Colonoscopy findings. The lesion can be seen protruding
from the submucosa.
Figure 4 Microscopic findings from a resected liver specimen. Tumor proliferation is evident adjacent to scar tissue (A) and has intersecting
fascicles of atypical spindle-cells (B). The tumor was immunohistochemically positive for SMA (C), desmin (D) and h-caldesmon (E), and negative
for c-KIT (F), CD34 (G) and S-100 (H). The blood vessel wall was positive for CD34 (G). A and B, H&E; C, SMA; D, desmin; E, h-caldesmon; F, C-kit; G,
CD34; and H, S-100.
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This combination of highly-specific immunohisto-
chemical findings provided a definitive diagnosis of
colon LMS and multiple liver metastases.
Moreover, in the diagnosis of the present case, LMSs in
both the liver and colon were possibly metastatic tumors
that originated from primary LMS in another organ. Actu-
ally, LMS of the left thigh that metastasized to the liver,
large bowel and lymph nodes has been reported [12].
However, in the present study, soft tissue tumor was not
detected using periodically-performed CT and PET-CT
scans in the course of treatment. Furthermore, we recently
performed additional immunohistochemical analyses for
gastric lesions to distinguish them from LMS. The biopsy
tissue of the gastric lesion was immunohistochemically
negative for desmin, SMA and h-caldesmon, and positive
for cytokeratin (AE1/AE3 and CAM5.2) (Figure 7B-F).
Figure 6 Microscopic findings from a resected colon specimen. The tumor developed from the muscular layer of the colon (A). Histological
and immunohistochemical findings for the colon and liver tumors were similar (B-H). The blood vessel wall and nerve tissues were positive for
CD34 (G) and S-100 (H), respectively. A and B, H&E; C, SMA; D, desmin; E, h-caldesmon; F, C-kit; G, CD34; and H, S-100.
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ferent histological picture and immunohistochemical pro-
files. Thus, we could conclude that this case represents a
combination of colonic LMS that metastasized to the liver
and gastric cancer.
Surgical resection is the most frequent approach to
treating LMS [2,6-8]. One report describing meta-
static sarcoma to the liver, that also included liver
metastases from GIST and extra-intestinal LMS, has
shown that the complete resection of liver metastases
from the sarcoma was associated with prolonged sur-
vival, and that the interval to metachronous metasta-
sis was an independent predictor of outcome [13].
Chemotherapy generally plays a limited role in the
treatment of LMS [13,14]. Furthermore, a specific
molecular therapy is currently available for GIST, but
not for LMS. Reports indicate that 30–60% clinicalresponse rates can be achieved in the treatment of
LMS using combinations of docetaxel and gemcita-
bine [15], and in the treatment of advanced soft tis-
sue sarcoma using ifosfamide with anthracycline and/or
dacarbazine [16-18]. Only first line chemotherapy with
docetaxel and S-1 was found to be effective against both
the gastric cancer and LMS in our patient. The overall re-
sponse rate of this regimen is reported to be 56.3% for gas-
tric cancer [5]. It was considered that docetaxel, which is
so frequently used and effective against both LMS and
gastric cancer, could simultaneously reduce the size of
these tumors.
We initially considered that the liver tumors were metas-
tases arising from gastric cancer. However, we resected the
stomach and liver tumors because all of the tumors
remained small. They proved to be completely resectable
and de novo lesions did not appear during the first year of
Figure 7 Additional immunohistochemical analyses of liver and gastric tumor. The liver tumor was immunohistochemically positive for
vimentin (A). The gastric tumor was negative for SMA (B), desmin (C) and h-caldesmon (D), and positive for AE1/AE3 (E) and CAM5.2 (F). The
blood vessel wall and fibrous tissue were positive for SMA (B), desmin (C) and h-caldesmon (D). A, vimentin; B, SMA; C, desmin; D, h-caldesmon;
E, AE1/AE3; and F, CAM5.2.
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ineffective and had the number of liver tumors and/or the
size of the gastric cancer increased, surgical resection in our
patient would not have been indicated. This was because of
the fact that these factors would have pointed to a decreased
probability of complete resection being achievable.
The tumorigenesis of gastric cancer and LMS has been
reported to involve various factors [19-22]. Common
factors, such as infection with the Epstein-Barr virus and
molecular alterations in RASSF1A, were also indicated in
the occurrence of these tumors [23,24]. Furthermore, in
an experimental model, simultaneous exposure to both
nitrosoguanidine and acetylsalicylic acid caused syn-
chronous development of both gastric cancer and LMS
[25]. Intragastric application of N-methylnitrosourea also
revealed increased susceptibility to chemical tumorigen-
esis of gastric cancer and sarcoma in p53 knockout mice
[26]. In the present case, it is not clear if the association is a
simple coincidental coexistence or if the two types of lesionare connected by a causal relationship that might involve a
common aetiology and tumorigenic mechanisms.
Colonic LMS is rare and its occurrence in combin-
ation with gastric cancer is extremely unusual. Although
the diagnosis in our patient was complicated by the
presence of both gastric cancer and LMS, an immuno-
histochemical study of surgical specimens confirmed the
final diagnosis of LMS of the sigmoid colon with mul-
tiple liver metastases. We concluded that the multimodal
approach comprising chemotherapy and complete surgical
resection controlled the LMS, even with multiple liver
metastases present, and improved the survival of this
patient.
Consent
Written informed consent was obtained from one of the
patients’ relatives for publication of this case report and
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